Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

By / 09/07/2024

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced it has resubmitted its BLA for approval of Ryoncil® in the treatment of children with SR-aGVHD.